angiotensin ii has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Chen, L; Cui, Y; Fei, L; Fu, X; Hu, W; Jiang, S; Labes, R; Lai, EY; Li, L; Patzak, A; Schmidt, MO; Tang, C; Wang, Q; Wang, X; Wei, Q; Wellstein, A; Wilcox, CS; Xu, N; Zhao, J; Zhao, L; Zheng, Z; Zhou, S | 1 |
1 other study(ies) available for angiotensin ii and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
Acute Kidney Injury Sensitizes the Brain Vasculature to Ang II (Angiotensin II) Constriction via FGFBP1 (Fibroblast Growth Factor Binding Protein 1).
Topics: Acute Kidney Injury; Angiotensin II; Animals; Brain; Intercellular Signaling Peptides and Proteins; Mesenteric Arteries; Mice, Inbred C57BL; Mice, Knockout; Phenylurea Compounds; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Reperfusion Injury; Vasoconstrictor Agents | 2020 |